Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

Dena Marrinucci, Kelly Bethel, Anand Kolatkar, Madelyn S. Luttgen, Michael Malchiodi, Franziska Baehring, Katharina Voigt, Daniel Lazar, Jorge Nieva, Lyudmila Bazhenova, Andrew H. Ko, W. Michael Korn, Ethan Schram, Michael Coward, Xing Yang, Thomas Metzner, Rachelle Lamy, Meghana Honnatti, Craig Yoshioka, Joshua KunkenYelena Petrova, Devin Sok, David Nelson, Peter Kuhn

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL -1 of blood in 80% of patients with metastatic prostate cancer (n = 20), in 70% of patients with metastatic breast cancer (n = 30), in 50% of patients with metastatic pancreatic cancer (n = 18), and in 0% of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.

Original languageEnglish (US)
Article number016003
JournalPhysical Biology
Volume9
Issue number1
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Pancreatic Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Biopsy
Neoplasms
Membrane Proteins
Pathology
Neoplasm Metastasis
Carcinoma

ASJC Scopus subject areas

  • Biophysics
  • Molecular Biology
  • Cell Biology
  • Structural Biology

Cite this

Marrinucci, D., Bethel, K., Kolatkar, A., Luttgen, M. S., Malchiodi, M., Baehring, F., ... Kuhn, P. (2012). Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Physical Biology, 9(1), [016003]. https://doi.org/10.1088/1478-3975/9/1/016003

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. / Marrinucci, Dena; Bethel, Kelly; Kolatkar, Anand; Luttgen, Madelyn S.; Malchiodi, Michael; Baehring, Franziska; Voigt, Katharina; Lazar, Daniel; Nieva, Jorge; Bazhenova, Lyudmila; Ko, Andrew H.; Korn, W. Michael; Schram, Ethan; Coward, Michael; Yang, Xing; Metzner, Thomas; Lamy, Rachelle; Honnatti, Meghana; Yoshioka, Craig; Kunken, Joshua; Petrova, Yelena; Sok, Devin; Nelson, David; Kuhn, Peter.

In: Physical Biology, Vol. 9, No. 1, 016003, 02.2012.

Research output: Contribution to journalArticle

Marrinucci, D, Bethel, K, Kolatkar, A, Luttgen, MS, Malchiodi, M, Baehring, F, Voigt, K, Lazar, D, Nieva, J, Bazhenova, L, Ko, AH, Korn, WM, Schram, E, Coward, M, Yang, X, Metzner, T, Lamy, R, Honnatti, M, Yoshioka, C, Kunken, J, Petrova, Y, Sok, D, Nelson, D & Kuhn, P 2012, 'Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers', Physical Biology, vol. 9, no. 1, 016003. https://doi.org/10.1088/1478-3975/9/1/016003
Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Physical Biology. 2012 Feb;9(1). 016003. https://doi.org/10.1088/1478-3975/9/1/016003
Marrinucci, Dena ; Bethel, Kelly ; Kolatkar, Anand ; Luttgen, Madelyn S. ; Malchiodi, Michael ; Baehring, Franziska ; Voigt, Katharina ; Lazar, Daniel ; Nieva, Jorge ; Bazhenova, Lyudmila ; Ko, Andrew H. ; Korn, W. Michael ; Schram, Ethan ; Coward, Michael ; Yang, Xing ; Metzner, Thomas ; Lamy, Rachelle ; Honnatti, Meghana ; Yoshioka, Craig ; Kunken, Joshua ; Petrova, Yelena ; Sok, Devin ; Nelson, David ; Kuhn, Peter. / Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. In: Physical Biology. 2012 ; Vol. 9, No. 1.
@article{37d58028ef79451fba3ded140584ddaf,
title = "Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers",
abstract = "Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL -1 of blood in 80{\%} of patients with metastatic prostate cancer (n = 20), in 70{\%} of patients with metastatic breast cancer (n = 30), in 50{\%} of patients with metastatic pancreatic cancer (n = 18), and in 0{\%} of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.",
author = "Dena Marrinucci and Kelly Bethel and Anand Kolatkar and Luttgen, {Madelyn S.} and Michael Malchiodi and Franziska Baehring and Katharina Voigt and Daniel Lazar and Jorge Nieva and Lyudmila Bazhenova and Ko, {Andrew H.} and Korn, {W. Michael} and Ethan Schram and Michael Coward and Xing Yang and Thomas Metzner and Rachelle Lamy and Meghana Honnatti and Craig Yoshioka and Joshua Kunken and Yelena Petrova and Devin Sok and David Nelson and Peter Kuhn",
year = "2012",
month = "2",
doi = "10.1088/1478-3975/9/1/016003",
language = "English (US)",
volume = "9",
journal = "Physical Biology",
issn = "1478-3967",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

AU - Marrinucci, Dena

AU - Bethel, Kelly

AU - Kolatkar, Anand

AU - Luttgen, Madelyn S.

AU - Malchiodi, Michael

AU - Baehring, Franziska

AU - Voigt, Katharina

AU - Lazar, Daniel

AU - Nieva, Jorge

AU - Bazhenova, Lyudmila

AU - Ko, Andrew H.

AU - Korn, W. Michael

AU - Schram, Ethan

AU - Coward, Michael

AU - Yang, Xing

AU - Metzner, Thomas

AU - Lamy, Rachelle

AU - Honnatti, Meghana

AU - Yoshioka, Craig

AU - Kunken, Joshua

AU - Petrova, Yelena

AU - Sok, Devin

AU - Nelson, David

AU - Kuhn, Peter

PY - 2012/2

Y1 - 2012/2

N2 - Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL -1 of blood in 80% of patients with metastatic prostate cancer (n = 20), in 70% of patients with metastatic breast cancer (n = 30), in 50% of patients with metastatic pancreatic cancer (n = 18), and in 0% of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.

AB - Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL -1 of blood in 80% of patients with metastatic prostate cancer (n = 20), in 70% of patients with metastatic breast cancer (n = 30), in 50% of patients with metastatic pancreatic cancer (n = 18), and in 0% of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.

UR - http://www.scopus.com/inward/record.url?scp=84856948211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856948211&partnerID=8YFLogxK

U2 - 10.1088/1478-3975/9/1/016003

DO - 10.1088/1478-3975/9/1/016003

M3 - Article

C2 - 22306768

AN - SCOPUS:84856948211

VL - 9

JO - Physical Biology

JF - Physical Biology

SN - 1478-3967

IS - 1

M1 - 016003

ER -